Home > Boards > US Listed > Biotechs > Biohaven Pharmceuticals (BHVN)

i don't know but it looks like they

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ronpopeil Member Profile
Member Level 
Followed By 115
Posts 8,671
Boards Moderated 1
Alias Born 10/05/04
160x600 placeholder
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With... PR Newswire (US) - 6/24/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/21/2019 4:06:57 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/20/2019 4:07:22 PM
Biohaven Announces Pricing Of $300 Million Public Offering Of Common Shares PR Newswire (US) - 6/18/2019 10:08:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/18/2019 6:02:55 AM
Biohaven Announces Proposed Public Offering Of Common Shares PR Newswire (US) - 6/17/2019 6:00:00 PM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 6/17/2019 5:15:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:39:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:38:26 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:37:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:36:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:35:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/23/2019 6:34:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/22/2019 5:19:50 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 5:33:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 6:44:00 AM
Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents... PR Newswire (US) - 5/7/2019 11:30:00 PM
Biohaven Advances Late Stage Clinical Programs And Novel Targets From Neuroinnovation Platforms PR Newswire (US) - 5/7/2019 11:15:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 4:54:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 11:31:55 AM
Biohaven Pharmaceuticals Reports First Quarter 2019 Financial Results And Advancements In Neuroinnovation Platforms PR Newswire (US) - 5/7/2019 6:55:00 AM
Biohaven Announces Late-Breaking Oral Presentation Of Rimegepant Zydis® ODT Phase 3 Results At American Academy Of Neurology... PR Newswire (US) - 5/3/2019 7:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/1/2019 6:03:29 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/16/2019 7:24:37 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/11/2019 5:24:22 PM
ronpopeil Member Level  Thursday, 03/01/18 08:29:45 PM
Re: bbhuey post# 4
Post # of 11 
i don't know but it looks like they are rebuilding the company. they have positions in several early stage companies so who knows. i feel at these levels the company is undervalued

"Don't worry about the world coming to an end today. It's already tomorrow in Australia"

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist